AbL Diagnostics SA (ABLD) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of AbL Diagnostics SA stock €0.57, price €2.44, that is 76.6% below the price, quality 75 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range €0.6378 – €15.27 · fair‑value band €0.4200 – €0.7800 · the €2.44 price screens above the €0.5700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow AbL Diagnostics in your weekly email
Every Wednesday you see whether AbL Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ABL Diagnostics provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.
Show moreShow less
The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction.
It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers.
The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics in April 2022. The company is headquartered in Woippy, France. ABL Diagnostics is a subsidiary of Advanced Biological Laboratories (ABL) S.A.
Stock analysis
AbL Diagnostics SA (ABLD) currently trades at €2.44, while our model-based Fair Value estimate is €0.5700, 77% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €1.02 per share, and 0 of the 22 models we run sit above the €2.44 price.
Bear case: the Asset-Based group reads lowest at €0.2600, and 22 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: €0.4200 (bear) to €0.7800 (bull), the price of €2.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
AbL Diagnostics SA reported revenue of €7.0M in FY2025 versus €0 in FY2021. Reported net income was €987K in FY2025.
Key figures
Market cap €39.2M Micro · P/E ratio 20.3 · P/S ratio 2.89 · EPS (TTM) €0.1200 · Dividend yield 4.5% · Net margin 14.2% · Return on equity 28.2% · Return on assets (EBIT) −1.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 70 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −77%, ABLD screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.1400 to €1.35). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear€0.4200Fair Value €0.5700Bull€0.7800
Price €2.44 · Downside -76.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0086 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+30.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.4%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.8%
’11
’12
’13
’14
’15
’16
’17
’18
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +74.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.0%
Dividend (yield on the price)4.5%
Profit margin 2007 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1,110% → 4%
⚠ Rate on operating basis: 2025 sits 247% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +28.6% a year for the price.
News mood ⓘNews mood, the average tone of recent news (2 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside−76.6% · Bottom 25%
Profitability
Return on equity (12 months)28.2% · Top 25%
Return on assets7.6% · Top 25%
Net margin (12 months)17.8% · Top 25%
Operating margin (12 months)17.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)96.4% · Top 25%
Dividend yield (12 months)4.5% · Above median
Balance sheet
Debt / equity0.18× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AbL Diagnostics SA Fair Value". https://www.fairvalue-calculator.com/stock/ABLD
Frequently asked questions
Is AbL Diagnostics SA (ABLD) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of €0.5700 versus a price of €2.44, about 77% lower (overvalued).
What is the fair value of ABLD?
Our model-based fair value for AbL Diagnostics SA is €0.5700 (as of Nov 7, 2026), built from audited fundamentals. The current price: €2.44.
What is the quality score of ABLD?
AbL Diagnostics SA has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AbL Diagnostics SA (ABLD)?
Our model-based price target is the fair value of €0.5700 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario €0.4200, optimistic scenario €0.7800. It is a calculation from audited fundamentals, not an analyst target.
What is the AbL Diagnostics SA stock forecast for 2026?
Our models put fair value at €0.5700, about 77% lower versus a price of €2.44 (overvalued). Cautious scenario €0.4200, optimistic scenario €0.7800. The calculation is refreshed regularly with new filings.
What is the revenue of AbL Diagnostics SA (ABLD)?
AbL Diagnostics SA reported trailing-twelve-month revenue of about €11.1M (latest available figure, as of Nov 7, 2026).
Does AbL Diagnostics SA pay a dividend?
AbL Diagnostics SA currently shows a dividend yield of 4.51% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of AbL Diagnostics SA (ABLD) and when is the ex-dividend date?
AbL Diagnostics SA pays a dividend of €0.11 per share a year, a dividend yield of 4.5%. The last ex-dividend date was Jul 3, 2026. The payout ratio is 91.7% of earnings. Free cash flow covers the dividend 0.40 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into AbL Diagnostics SA (ABLD)?
For today's price to be fair in a discounted-cash-flow model, AbL Diagnostics SA would have to grow free cash flow by +31.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 7 years revenue grew +53.7 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ABLD use?
Our models discount AbL Diagnostics SA at 10.3 %: a base by market capitalisation (nano), country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AbL Diagnostics SA that is +31.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has AbL Diagnostics SA (ABLD) delivered so far?
Over the past 7 years revenue at AbL Diagnostics SA grew +53.7 % a year. The price currently implies free-cash-flow growth of +31.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AbL Diagnostics SA (ABLD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into AbL Diagnostics SA (+31.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AbL Diagnostics SA (ABLD)?
The free-cash-flow yield on the price is 1.82 %: that much free cash flow AbL Diagnostics SA produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AbL Diagnostics SA (ABLD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AbL Diagnostics SA it is €0.5700 per share (as of Nov 7, 2026), against a price of €2.44. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is AbL Diagnostics SA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ABLD trades above its calculated fair value: price €2.44, fair value €0.5700, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABLD?
No. The price is what the market pays today (€2.44); the fair value is what the company's own numbers justify (€0.5700). For AbL Diagnostics SA the two are €1.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is AbL Diagnostics SA worth?
The market values AbL Diagnostics SA at about €39.2M (market capitalisation, as of Nov 7, 2026). Per share that is €2.44; our models calculate a fair value of €0.5700 per share.
What do the bullish and bearish scenarios say about ABLD?
Our models span a range for AbL Diagnostics SA: cautious scenario €0.4200, base €0.5700, optimistic €0.7800 per share (as of Nov 7, 2026, price €2.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ABLD?
AbL Diagnostics SA trades at a price-to-earnings ratio of 20.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.5700 is built from several models across several years. Other multiples: PEG 1.9, P/B 5.1, P/S 3.5, EV/EBITDA 30.4.
What is the PEG ratio of ABLD?
The PEG ratio of AbL Diagnostics SA is 1.94 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of AbL Diagnostics SA (ABLD)?
Balance-sheet figures for AbL Diagnostics SA (as of Nov 7, 2026): return on equity 28.2%, debt of 0.18 per unit of equity. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is ABLD from its 52-week high?
AbL Diagnostics SA trades at €2.44, about 45% below its 52-week high of €4.41 and 15% above the low of €2.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5700 is for.
Which stocks are comparable to AbL Diagnostics SA?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AbL Diagnostics SA stock attractive at the current price?
The data as of Nov 7, 2026: price €2.44, calculated fair value €0.5700 (−77%), Quality Score 75/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABLD calculated?
We run AbL Diagnostics SA through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €0.5700 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. AbL Diagnostics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AbL Diagnostics SA (ABLD)?
The closing price on Nov 6, 2026 was €2.44. Our model-based fair value is €0.5700, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AbL Diagnostics SA right now?
A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (€0.7800). The favourable scenario is already priced in. A fairly wide model range (€0.4200 to €0.7800) leaves room in how you read the outcome.
Key figures of AbL Diagnostics SA
How large is the market capitalisation of AbL Diagnostics SA (ABLD)?
The market capitalisation of AbL Diagnostics SA is €39.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AbL Diagnostics SA (ABLD)?
The price-to-sales ratio of AbL Diagnostics SA is 2.89 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AbL Diagnostics SA (ABLD)?
Earnings per share at AbL Diagnostics SA are €0.1200 (price ÷ EPS = P/E 20.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AbL Diagnostics SA (ABLD)?
The dividend yield of AbL Diagnostics SA is 4.5% (payout 91.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AbL Diagnostics SA (ABLD)?
The net margin of AbL Diagnostics SA is 14.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AbL Diagnostics SA (ABLD)?
The return on equity (ROE) of AbL Diagnostics SA is 28.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AbL Diagnostics SA (ABLD)?
On an EBIT basis the return on assets of AbL Diagnostics SA is −1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AbL Diagnostics SA (ABLD)?
The operating margin of AbL Diagnostics SA is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AbL Diagnostics SA (ABLD)?
Revenue at AbL Diagnostics SA is growing +96.4% versus a year earlier (3y avg −7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AbL Diagnostics SA (ABLD)?
Earnings per share at AbL Diagnostics SA are growing +301% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does AbL Diagnostics SA (ABLD) carry?
The net debt of AbL Diagnostics SA is €1.2M (fiscal year 2025, ≈ 1.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch AbL Diagnostics SA in the live analysis
One click puts AbL Diagnostics SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026